

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549  
SCHEDULE 14A  
(Rule 14a-101)  
INFORMATION REQUIRED IN PROXY STATEMENT  
SCHEDULE 14A INFORMATION  
Proxy Statement Pursuant to Section 14(a)  
of the Securities Exchange Act of 1934

Filed by the Registrant  [X]

Filed by a Party other than the Registrant  [ ]

Check the appropriate box:

- [ ] Preliminary Proxy Statement
- [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(c)(2))
- [ ] Definitive Proxy Statement
- [X] Definitive Additional Materials
- [ ] Soliciting Material Pursuant to §240.14a-12

PROPHASE LABS, INC.  
(Name of Registrant as Specified in Its Charter)

Payment of Filing Fee (Check the appropriate box):

[X] No fee required.

[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

- (1) Title of each class of securities to which transaction applies:
- (2) Aggregate number of securities to which transaction applies:
- (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
- (4) Proposed maximum aggregate value of transaction:
- (5) Total fee paid:

[ ] Fee paid previously with preliminary materials:

[ ] Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

- (1) Amount Previously Paid:
  - (2) Form, Schedule or Registration Statement No.:
  - (3) Filing Party:
  - (4) Date Filed:
-

On April 5, 2011, ProPhase Labs, Inc. delivered the following letter to certain record holders of its common stock:



April 5, 2011

Dear Fellow Stockholders,

You recently received proxy materials in connection with the 2011 Annual Meeting of Stockholders of ProPhase Labs, Inc. In addition to the election of directors and the ratification of independent auditors, stockholders are being asked to approve an amendment to the 2010 Equity Compensation Plan.

- **The amendment will align employees' compensation more closely to the Company's performance and provide the Company with the ability to pay a portion of the employees' compensation in stock based compensation instead of cash, thereby strengthening the cash flow and working capital positions of the Company.**

Your board of directors unanimously recommends that you vote "FOR" each of the three proposals. In addition, ISS, the leading independent proxy advisory firm is recommending that its clients vote "FOR" all of the proposals.

According to our latest records, **YOUR PROXY VOTE HAS NOT YET BEEN RECEIVED**. Please sign, date and mail the enclosed proxy card in the postage-paid envelope that has been provided.

Your vote is important. Please vote today.

Thank you in advance for your support and for acting promptly.

On behalf of your Board of Directors,

A handwritten signature in black ink, appearing to read "TK", is written over a faint, light-colored signature line.

Ted Karkus  
Chairman of the Board, CEO

621 N. Shady Retreat Road • Doylestown, PA 18901-1349 • U.S.A.  
Telephone: 215-345-0919 • Fax: 215-345-5920 • For information: [www.ProPhaseLabs.com](http://www.ProPhaseLabs.com)

*Putting the Care in Health*

---

**Important Additional Information**

ProPhase Labs, Inc. (the "Company") filed a definitive proxy statement with the Securities and Exchange Commission (the "SEC") on March 16, 2011 in connection with its 2011 Annual Meeting of Stockholders and began the process of mailing the definitive proxy statement and a proxy card to stockholders on March 21, 2011. The Company's stockholders are strongly advised to read the Company's proxy statement as it contains important information. Stockholders may obtain an additional copy of the definitive proxy statement and any other documents filed by the Company with the SEC for free at the SEC's website at <http://www.sec.gov>. Copies of the definitive proxy statement are available for free at <http://www.amstock.com/ProxyServices/ViewMaterial.asp?CoNumber=07814>.

**Forward-Looking Statements**

Certain statements in this communication are "forward-looking statements" and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions; government regulations; the ability of our management to successfully implement our business plan and strategy; our ability to fund our operations including the cost and availability of capital and credit; our ability to compete effectively including our ability to maintain and increase our market share in the markets in which we do business; our dependence on sales from our main produce, Cold-EEZE®, and our ability to successfully develop and commercialize new products; seasonal fluctuations in demand for our products; our ability to attract, retain and motivate key employees; and the ability of Phusion Laboratories, LLC, a 50% owned joint venture, to successfully implement its business plan and strategy to develop and commercialize one or more non-prescription remedies using certain patented and proprietary technology.

---